Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

Inclusion Criteria: 1. ≥18 years old 2. histologically or cytologically confirmed non-squamous NSCLC with documented EGFR uncommon mutations from a local laoratory. at least one EGFR uncommon mutation (excluding EGFR 19del/l858r/T790m/Ex 20ins ) or compund mutations with EGFR uncommon mutations. 3. predicted life expectancy ≥ 12 weeks. 4. patient must have measurable disease according to RECIST 1.1 Exclusion Criteria: 1. previos systemic anti-tumor therapy 2. a history of malignant tumors within 2years 3. any severa or poorly controlled systemic disease per investigator's judgement 4. active infections